Photo Credit: washingtonpost.com
Amber Syed – Scene Editor
Pfizer and BioNtech announced, earlier this week, that they found their vaccine to be over 90% effective in phase 3.
Their study includes 43,538 participants, of which 43% have diverse backgrounds. Ater comparing the participants who received the placebo compared to participants who received the second dose of the actual vaccine, scientists concluded the efficacy rate of the vaccine is over 90%.
According to Pfizer, “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer CEO and Chairman.
The company projects to have 50 million vaccine doses in 2020 and up to 1.3 million doses in 2021 globally.